製品番号: HY-109038

Mocravimod

(別名: KRP-203 free base)

2 Cited Publications

カスタマーレビュー

Based on 2 publication(s) in Google Scholar

Mocravimod (KRP-203 free base) is a sphingosine-1-phosphate receptor (S1PR) modulator that blocks the signal required by T cells to egress from lymph nodes and other lymphoid organs. Mocravimod preferentially binds to S1PR1 over S1PR2 and S1PR3 in cardiomyocytes. Mocravimod significantly lowered the concentration of reactive oxygen species (ROS), prevented mitochondrial permeability transition pore opening, boosted mitochondrial membrane potential (MMP), and increased phosphorylation of AKT, EKR, GSK-3β, JAK2, and STAT3. Mocravimod retains T cell effector function. Mocravimod can be used for the study of acute myelogenous leukemia, diabetes and Myocardial Ischemia-Reperfusion Injury (MIRI).

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 98.39%
CAS 番号: 509092-16-4
分子式: C₂₄H₂₆ClNO₃S
分子量:443.99

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Mocravimod 構造式

CAS 番号: 509092-16-4

容量

価格（税別）

在庫状況

数量

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

お問い合わせ Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability お問い合わせ Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

バルクお問い合わせ

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- 体外実験
- 体内実験
化学情報
Publications (2)
溶剤 & 溶解度
- 体外
純度とドキュメンテーション
参考文献
Help & FAQs
Bioz

生物活性

製品説明

IC₅₀ & Target

S1PR1

GSK-3β

STAT3

JAK2

LPL Receptor アイソフォーム固有の製品をすべて表示 :

Akt アイソフォーム固有の製品をすべて表示 :

GSK-3 アイソフォーム固有の製品をすべて表示 :

JAK アイソフォーム固有の製品をすべて表示 :

STAT アイソフォーム固有の製品をすべて表示 :

体外実験

Mocravimod (0.2-5 μM, 24 h) significantly improves the survival rate of the hypoxia-reoxygenation (H/R) H9c2 cells, reduces lactate dehydrogenase (LDH) release, and decreases apoptosis^[4].
Mocravimod (0.2-1 μM, 24 h) significantly reduces reactive oxygen species (ROS) levels, improves mitochondrial membrane potential, and inhibits the opening of the mitochondrial permeability transition pore (mPTP) in hypoxia-reoxygenation (H/R) H9c2 cells^[4].
Mocravimod (0.2-1 μM, 24 h) inhibits the expression of mitochondrial-mediated apoptosis pathway proteins such as cytochrome C, caspase-9, and caspase-3^[4].
Mocravimod (0.2-1 μM, 24 h) significantly increases the phosphorylation levels of key signaling pathway proteins in hypoxia-reoxygenation (H/R) H9c2 cells, including AKT (Ser473), ERK (Thr202/Tyr204), GSK-3β (Ser9), JAK2 (Tyr1007/1008), and STAT3 (Ser727)^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[4]

Cell Line:

Hypoxia-Reoxygenation (H/R) H9c2 Cells
Concentration:

0.2 μM, 1 μM, 5 μM
Incubation Time:

24 h
Result:

Induced apoptosis.

Western Blot Analysis^[4]

Cell Line:

Hypoxia-Reoxygenation (H/R) H9c2 Cells
Concentration:

0.2 μM, 1 μM
Incubation Time:

24 h
Result:

Inhibited the expression of mitochondrial-mediated apoptosis pathway proteins such as cytochrome C, caspase-9, and caspase-3.

体内実験

Mocravimod (once daily/twice daily, 1-5 days) significantly improves the survival rate of islet transplantation in C57BL/6 mice with diabetes induced by intravenous Streptozotocin (HY-13753)^[2].
Mocravimod (3.0 mg/kg, i.p., thrice weekly) significantly inhibits the development of atherosclerotic lesions in mice on a high-cholesterol diet, and this effect was independent of changes in blood lipids, but rather by regulating the infiltration of inflammatory cells within plaques^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Low-density lipoprotein receptor-deficient mice (LDL-R-/-) on cholesterol-rich diet^[3].
Dosage:

3 mg/kg
Administration:

I.p., thrice weekly for 6-16 weeks
Result:

Significantly reduced the lesion area of the aortic root and the entire aorta.
Decreased levels of macrophages (MOMA-2 positive) and T cells (CD3 positive) in plaques.
No effect on plasma lipid levels (total cholesterol, HDL cholesterol, triglycerides), body weight, or liver and kidney function parameters (such as ALT, BUN, creatinine).
Decreased CD4+ and CD8+ T cells in the spleen and lymph nodes, with decreased expression of the activation marker CD69.
Decreased MHC-II expression (activation marker) in F4/80+ macrophages and CD11c+ dendritic cells; reduced cytokine (TNF-α, MCP-1, IL-6) production after in vitro stimulation.

化学情報

CAS 番号 509092-16-4
性状 Solid
分子量 443.99
分子式 C₂₄H₂₆ClNO₃S
Color White to off-white
SMILES

OCC(CCC1=CC=C(SC2=CC=CC(OCC3=CC=CC=C3)=C2)C=C1Cl)(N)CO
別名

KRP-203 free base
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (2)

All

Sort by:

Journal Impact Factor

Cell Biol Toxicol

The novel sphingosine-1-phosphate receptor modulator KRP-203 prevents myocardial ischemia-reperfusion injury by preserving mitochondrial function through activation of the RISK and SAFE signaling pathways. [Abstract]

2025 Nov 27;41(1):159. PMID: 41307722
bioRxiv

Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors. [Abstract]

2025 Nov 24:2025.11.21.689510. PMID: 41341164

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (225.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2523 mL

11.2615 mL

22.5230 mL

5 mM

0.4505 mL

2.2523 mL

4.5046 mL

10 mM

0.2252 mL

1.1262 mL

2.2523 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (277 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Dertschnig S, et al. Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for Malignancy. Transplant Cell Ther. 2023 Jan;29(1):41.e1-41.e9. [Content Brief]

[2]. Suzuki et al. PS11.7: Mocravimod, a novel immunosuppressant, not only suppresses immune rejection but also promotes engraftment of intraportally transplanted islets by its anti-inflammatory and anti-coagulant effects.

[3]. Potì F, et al. Mocravimod, sphingosine 1-phosphate receptor type 1 agonist, ameliorates atherosclerosis in LDL-R-/- mice. Arterioscler Thromb Vasc Biol. 2013 Jul;33(7):1505-12. [Content Brief]

[4]. Wu N, et al. The novel sphingosine-1-phosphate receptor modulator Mocravimod prevents myocardial ischemia-reperfusion injury by preserving mitochondrial function through activation of the RISK and SAFE signaling pathways. Cell Biol Toxicol. 2025 Nov 27;41(1):159. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2523 mL	11.2615 mL	22.5230 mL	56.3076 mL
	5 mM	0.4505 mL	2.2523 mL	4.5046 mL	11.2615 mL
	10 mM	0.2252 mL	1.1262 mL	2.2523 mL	5.6308 mL
	15 mM	0.1502 mL	0.7508 mL	1.5015 mL	3.7538 mL
	20 mM	0.1126 mL	0.5631 mL	1.1262 mL	2.8154 mL
	25 mM	0.0901 mL	0.4505 mL	0.9009 mL	2.2523 mL
	30 mM	0.0751 mL	0.3754 mL	0.7508 mL	1.8769 mL
	40 mM	0.0563 mL	0.2815 mL	0.5631 mL	1.4077 mL
	50 mM	0.0450 mL	0.2252 mL	0.4505 mL	1.1262 mL
	60 mM	0.0375 mL	0.1877 mL	0.3754 mL	0.9385 mL
	80 mM	0.0282 mL	0.1408 mL	0.2815 mL	0.7038 mL
	100 mM	0.0225 mL	0.1126 mL	0.2252 mL	0.5631 mL

Mocravimod

2 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Mocravimod

Epigenetics Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Mitochondria-Targeted Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Rare Diseases Drug Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Cuproptosis Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

MedChemExpress（MCE）の使用を引用している文献 Mocravimod

LPL Receptor アイソフォーム固有の製品をすべて表示

Akt アイソフォーム固有の製品をすべて表示

GSK-3 アイソフォーム固有の製品をすべて表示

JAK アイソフォーム固有の製品をすべて表示

STAT アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (2)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Mocravimod 関連分類

製品番号: HY-109038